Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.
Global Virus Network (GVN) Centre of Excellence in Arboviruses, Griffith University, Gold Coast, QLD, Australia.
Br J Pharmacol. 2023 Jan;180(2):133-143. doi: 10.1111/bph.15987. Epub 2022 Nov 30.
A cytokine storm is one of the leading causes of acute respiratory distress syndrome (ARDS) and sepsis-associated multiple organ failure in many respiratory viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The coronavirus disease 2019 (COVID-19) pandemic has caused millions of deaths worldwide, resulting in an urgent need for effective therapeutic interventions. Repurposing immunosuppressive drugs that target cytokines with immunomodulatory properties is a promising approach to counteract SARS-CoV-2-induced ARDS at the infective and post-infective stages. In this minireview, we examine drugs targeting IL-1β, IL-4/IL-13, IL-6 and TNF-α tested in COVID-19 patients.
细胞因子风暴是许多呼吸道病毒感染中急性呼吸窘迫综合征(ARDS)和与脓毒症相关的多器官衰竭的主要原因之一,包括严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)。 2019 年冠状病毒病(COVID-19)大流行在全球范围内造成数百万人死亡,因此迫切需要有效的治疗干预措施。重新利用具有免疫调节特性的靶向细胞因子的免疫抑制剂是在感染和感染后阶段对抗 SARS-CoV-2 诱导的 ARDS 的一种有前途的方法。在这篇简评中,我们研究了针对 COVID-19 患者的靶向白细胞介素 1β(IL-1β)、白细胞介素 4/白细胞介素 13(IL-4/IL-13)、白细胞介素 6(IL-6)和肿瘤坏死因子-α(TNF-α)的药物。